2022
DOI: 10.1038/s41467-022-29125-7
|View full text |Cite
|
Sign up to set email alerts
|

N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis

Abstract: Mis-regulated RNA modifications promote the processing and translation of oncogenic mRNAs to facilitate cancer progression, while the molecular mechanisms remain unclear. Here we reveal that tRNA m7G methyltransferase complex proteins METTL1 and WDR4 are significantly up-regulated in esophageal squamous cell carcinoma (ESCC) tissues and associated with poor ESCC prognosis. In addition, METTL1 and WDR4 promote ESCC progression via the tRNA m7G methyltransferase activity in vitro and in vivo. Mechanistically, ME… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
75
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 100 publications
(77 citation statements)
references
References 50 publications
1
75
1
Order By: Relevance
“…Major limitations of the treatment of ESCC include high toxicity and acquired therapeutic resistance to chemotherapy and radiotherapy, as well as the high recurrence rate of surgery ( Leng et al, 2020 ). In recent years, although some clinical advances have been made in the development of diagnosis and therapeutic techniques, the overall 5-year survival rate for ESCC patients is still very poor ( Han et al, 2022 ). Consequently, it is pressingly needed to facilitate the development of effective strategies for ESCC therapy.…”
Section: Introductionmentioning
confidence: 99%
“…Major limitations of the treatment of ESCC include high toxicity and acquired therapeutic resistance to chemotherapy and radiotherapy, as well as the high recurrence rate of surgery ( Leng et al, 2020 ). In recent years, although some clinical advances have been made in the development of diagnosis and therapeutic techniques, the overall 5-year survival rate for ESCC patients is still very poor ( Han et al, 2022 ). Consequently, it is pressingly needed to facilitate the development of effective strategies for ESCC therapy.…”
Section: Introductionmentioning
confidence: 99%
“…Intriguingly, regulators of the m7G modification are aberrantly expressed in various cancers and may act as novel biomarkers for diagnosis and prognostic prediction. The m7G regulator METTL1 is significantly overexpressed and promotes tumorigenesis and development in AML, BC, ESCC, glioma, HCC, HNSCC, ICC, LC, and NPC, and high expression levels of METTL1 often predict poor survival in these patients [ 26 , 43 , 52 , 56 , 59 , 60 , 66 , 68 , 78 ]. WDR4 is also highly expressed and increases malignant phenotypes in multiple malignancies, including AML, ESCC, HCC, HNSCC, IC, LC, and NPC.…”
Section: Discussionmentioning
confidence: 99%
“…WDR4 is also highly expressed and increases malignant phenotypes in multiple malignancies, including AML, ESCC, HCC, HNSCC, IC, LC, and NPC. Increased expression of WDR4 is regarded as an unfavorable prognostic biomarker in such cancers [ 24 , 43 , 52 , 59 , 66 , 68 , 78 ]. In addition, METTL1 expression is associated with extremely poor prognosis in KIRC and mesothelioma, while it is related to superior survival in patients with ovarian serous cystadenocarcinoma [ 56 ].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations